Oxidative stress resistance and fitness-compensatory response in vancomycin-intermediate Staphylococcus aureus (VISA)

被引：2
|
作者：
Tan, Xin-Ee [1 ,3 ]
Neoh, Hui-min [1 ,2 ]
Cui, Longzhu [3 ]
Hiramatsu, Keiichi [2 ]
Jamal, Rahman [1 ]
机构：
[1] Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst UMBI, Bangi, Malaysia
[2] Juntendo Univ, Sch Med, Dept Bacteriol, Tokyo, Japan
[3] Jichi Med Univ, Sch Med, Dept Infect & Immun, Div Bacteriol, Shimotsuke, Tochigi, Japan
来源：
CANADIAN JOURNAL OF MICROBIOLOGY | 2019年 / 65卷 / 08期
关键词：
vancomycin-intermediate Staphylococcus aureus; oxidative stress; virulence; fitness cost; METHIONINE SULFOXIDE REDUCTASES; VIRULENCE; MODEL;
D O I：
10.1139/cjm-2019-0048
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In this study, vancomycin-intermediate Staphylococcus aureus (VISA) cells carrying vraS and (or) graR mutations were shown to be more resistant to oxidative stress. Caenorhabditis elegans infected with these strains in turn demonstrated lower survival. Altered regulation in oxidative stress response and virulence appear to be physiological adaptations associated with the VISA phenotype in the Mu50 lineage.
引用
收藏
页码：623 / 628
页数：6
相关论文
共 50 条
  • [31] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [32] Aortic Root Abscess with Aorta to Right Atrium Fistula due to Vancomycin-Intermediate Staphylococcus aureus (VISA)
    Hankinson, Stephen J.
    Sultanik, Elliot A.
    Ramani, Gautam V.
    CASE REPORTS IN CARDIOLOGY, 2019, 2019
  • [33] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [34] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [35] Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus
    Chapman, Jenelle E.
    George, Shilpa E.
    Wolz, Christiane
    Olson, Michael E.
    INFECTION GENETICS AND EVOLUTION, 2024, 117
  • [36] Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
    Lin, Lee-Chung
    Chang, Shih-Cheng
    Ge, Mao-Cheng
    Liu, Tsui-Ping
    Lu, Jang-Jih
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 113 - 123
  • [37] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638
  • [38] Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Kelley, Peter G.
    Gao, Wei
    Ward, Peter B.
    Howden, Benjamin P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1057 - 1060
  • [39] DIFFERENTIAL INFLAMMATORY RESPONSES IN MACROPHAGES BY VANCOMYCIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS AND VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS
    Lee, H. -S.
    Kuo, T. -Y.
    INFLAMMATION RESEARCH, 2011, 60 : 159 - 159
  • [40] Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA
    Lai, Chih-Cheng
    Chen, Chi-Chung
    Chuang, Yin-Ching
    Tang, Hung-Jen
    SCIENTIFIC REPORTS, 2017, 7
12345